BioSpace News Archive

Demand for cloud computing applications in healthcare facilities like laboratories and hospitals to monitor patient-specific health information will expand the healthcare cloud computing market forecast over the coming years.

Ortho Clinical Diagnostics Holdings plc (“Ortho”), the world’s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its initial public offering of 76 million ordinary shares at $17.00 per share

Surge in the number of people suffering from sleep related disorders could propel the home sleep apnea testing devices market size.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced the pricing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share.

Intragastric balloon, or stomach balloon placement is a non-surgical medical procedure which helps in reducing obesity.

Hormones are chemicals that are naturally produced by the organs and regulate just about every cell in the body. Hormone therapy is also known as endocrine therapy.

Pericardium is a double layered, tough membrane which covers the heart. Porcine and bovine pericardium is harvested and processed as a biomaterial and used in various clinical applications.

A gallbladder is a small, pear-shaped organ located on the right side of the abdomen, just beneath the liver in the human body.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain.

Shasqi, a clinical-stage biotechnology company developing precision oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACTM) platform, announced today the publication of two preclinical studies highlighting the potential of the company’s click chemistry-based approach to the development of treatments for a range of solid cancers.